Renalytix plc
Close on Oct 19, 2026
- Market cap
- $375.75M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q1 FY2025 Ended Sep 30, 2024 | Oct 1, 2024 | During market hours | – | – | – |
| Q3 FY2024 Ended Mar 31, 2024 | May 15, 2024 | Before market open | $500.00K | – | – |
| Q2 FY2024 Ended Dec 31, 2023 | Feb 15, 2024 | Before market open | $700.00K | $-0.09 | – |
| Q1 FY2024 Ended Sep 30, 2023 | Nov 14, 2023 | Before market open | $500.00K | – | – |
| Q4 FY2023 Ended Jun 30, 2023 | Sep 28, 2023 | Before market open | – | – | – |
Press releases
Announcements Renalytix filed with the SEC
LONDON and NEW YORK, 19 December 2024 –
Shareholder vote results · Regulation FD disclosure · EX-99.1 to Form 8-K
(“ Renalytix ” or the “ Company ”)
Executive or director change · Shareholder vote results · Regulation FD disclosure · EX-99.1 to Form 8-K
LONDON and NEW YORK, 31 October 2024 –
Executive or director change · Shareholder vote results · Regulation FD disclosure · EX-99.2 to Form 8-K
Update on financial results for the fiscal year ended 30 June 2024
Material agreement · Acquisition or disposition completed · Results of operations · New financial obligation · Listing notice · Unregistered share sale · Other events · EX-99.1 to Form 8-K
THIS ANNOUNCEMENT, INCLUDING THE APPENDICES TO THIS ANNOUNCEMENT, AND THE INFORMATION CONTAINED HEREIN, IS RESTRICTED AND IS NOT FOR PUBLICATION, DISTRIBUTION
Material agreement · Acquisition or disposition completed · Results of operations · New financial obligation · Listing notice · Unregistered share sale · Other events · EX-99.2 to Form 8-K
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN (TOGETHER THIS ANNOUNCEMENT) IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR
Material agreement · Acquisition or disposition completed · Results of operations · New financial obligation · Listing notice · Unregistered share sale · Other events · EX-99.3 to Form 8-K
Renalytix’s American Depositary Shares (“ADSs”) will Continue Trading on The Nasdaq Capital Market Effective at the Open of Trading on August 27, 2024
Listing notice · Regulation FD disclosure · EX-99.1 to Form 8-K
Issue of Shares and Rule 2.9 Announcement
Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Medicare Issues Final Coverage Determination for kidneyintelX.dkd
Regulation FD disclosure · EX-99.1 to Form 8-K
For further information, please contact:
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Renalytix Reports Financial Results for Third Quarter of Fiscal Year 2024
Results of operations · EX-99.1 to Form 8-K
Allotment and issue of the Second Tranche Placing Shares
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
After settlement of the repayment, the principal remaining under the convertible bonds will be reduced by $1.06 million to $12.72 million.
Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
KidneyIntelX included in Final KDIGO 2024 Clinical Guideline for Chronic Kidney Disease (CKD)
Regulation FD disclosure · EX-99.1 to Form 8-K
Renalytix announces the launch of an equity placing of Ordinary Shares of approximately US$10 million
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Successful completion of upsized $12 million equity placing
Material agreement · Unregistered share sale · Other events · EX-99.2 to Form 8-K
Renalytix Reports Financial Results for Second Quarter of Fiscal Year 2024
Results of operations · EX-99.1 to Form 8-K
Centers for Medicare & Medicaid Services Publishes Draft Local Coverage Determination
Regulation FD disclosure · EX-99.1 to Form 8-K
Update on kidneyIntelX.dkd Local Coverage Determination Consideration
Regulation FD disclosure · EX-99.1 to Form 8-K
New published data demonstrates KidneyIntelX has broad implications for winning war on chronic kidney disease
Regulation FD disclosure · EX-99.1 to Form 8-K
After settlement of the repayment, the principal remaining under the convertible bond will be reduced by $1.06 million to $13.78 million.
Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Renalytix Reports Financial Results for First Quarter of Fiscal Year 2024
Results of operations · EX-99.1 to Form 8-K
Publication of Annual Report 2023
Regulation FD disclosure · EX-99.1 to Form 8-K
After settlement of the repayment, the principal remaining under the convertible bond will be reduced by $1.06 million to $14.84 million.
Regulation FD disclosure · EX-99.1 to Form 8-K
Renalytix Reports Full Year Fiscal 2023 Results
Results of operations · EX-99.1 to Form 8-K
Renalytix Appoints Senior Executive Howard Doran as Chief Business Officer
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
The following amendment has been made to the ‘Issue of Shares’ announcement released on 17 July 2023 at 07:00 under RNS No 1495G
Regulation FD disclosure · EX-99.1 to Form 8-K
Renalytix Appoints Financial Executive Catherine Coste to its Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Renalytix plc – Notice of General Meeting
EX-99.1 to Form 6-K
Notice of General Meeting and Posting of Circular
EX-99 to Form 6-K
FOR THE YEAR ENDED 30 JUNE 2022
EX-99.1 to Form 6-K
Renalytix plc – Annual Report 2022 and Notice of 2022 Annual General Meeting
EX-99.2 to Form 6-K